A scheme to tackle the dilemma from hepatoma cells under doxorubicin-resistant surroundings: a brightness or a silhouette
Source abstract
Abstract
Background The aim of this study was to investigate key target(s), mechanism(s) from hepatoma cells in harsh doxorubicin-resistant conditions (DRCs) from GSE125180 datasets in GEO (Gene Expression Omnibus).Methods The identified components can be denoted as a brightness (therapeutic mark) or darkness (resistant mark) in DRCs. The protein-protein interaction (PPI) networks were assembled to identify the relationships between upregulated and downregulated genes via STRING, and R program.Results In the |log2 FC| > 1, and |log2 FC| > 2 subgroups, the uppermost target was a non-receptor tyrosine kinase (SRC) downregulated in DRCs, indicating that the dampened SRC is a therapeutic mark by doxorubicin (DOX). In contrast, in the |log2 FC| > 3 subgroup, the most significant target was Cluster of Differentiation 93 (CD93) upregulated in DRCs, suggesting that the overexpressed CD93 is a resistant mark in DRCs. Metoclopramide (MET) @ CD93 + DOX conformer is a highlighted capture to illuminate as combination therapy to overcome DRCs because MET is an inhibitor against CD93 as well as a non-competitive inhibitor on (MET @ CD93 + DOX) conformer.Conclusions These findings provide a mechanistic rationale for repurposing MET as an adjuvant agent to enhance therapeutic efficacy and overcome drug resistance in combination treatment strategies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Liver physiology and pathology · Lung Cancer Treatments and Mutations · Hepatocellular Carcinoma Treatment and Prognosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute for Liver and Digestive Diseases, College of Medicine, Hallym University
Funding
Hallym University Research Fund · the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology · Bio Industrial Technology Development Program funded by the Ministry of Trade, Industry and Energy · Korea Institute for Advancement of Technology funded by the Ministry of Trade, Industry and Energy
References (70)
Show source-provided references
1. 10.3390/DISEASES1307020710.3390/DISEASES13070207 ↗
2. 10.1097/CM9.000000000000326410.1097/CM9.0000000000003264 ↗
3. 10.17998/JLC.2024.03.1310.17998/JLC.2024.03.13 ↗
4. 10.3390/V1405098610.3390/V14050986 ↗
5. 10.1186/S11658-025-00745-310.1186/S11658-025-00745-3 ↗
6. 10.1038/s41598-025-26310-810.1038/s41598-025-26310-8 ↗
7. 10.1038/s44355-025-00038-810.1038/s44355-025-00038-8 ↗
8. 10.1038/S41416-025-02969-810.1038/S41416-025-02969-8 ↗
9. 10.12965/JER.2550482.24110.12965/JER.2550482.241 ↗
10. 10.3389/FIMMU.2024.136626010.3389/FIMMU.2024.1366260 ↗
11. 10.1186/S12943-024-02212-710.1186/S12943-024-02212-7 ↗
12. 10.1002/MCO2.26510.1002/MCO2.265 ↗
13. 10.1016/J.CPT.2025.07.00110.1016/J.CPT.2025.07.001 ↗
14. 10.1038/s41423-025-01308-410.1038/s41423-025-01308-4 ↗
15. 10.1186/S43556-026-00433-410.1186/S43556-026-00433-4 ↗
16. 10.1038/s41392-025-02142-w10.1038/s41392-025-02142-w ↗
17. 10.1186/S12935-025-03946-010.1186/S12935-025-03946-0 ↗
18. 10.1002/MCO2.26110.1002/MCO2.261 ↗
19. 10.3390/BIOMEDICINES1204091510.3390/BIOMEDICINES12040915 ↗
20. 10.1016/B978-008055232-3.61650-210.1016/B978-008055232-3.61650-2 ↗
21. 10.1016/J.IJPHARM.2024.12442410.1016/J.IJPHARM.2024.124424 ↗
22. 10.3390/CELLS1204065910.3390/CELLS12040659 ↗
23. 10.1016/J.BIOPHA.2021.11170810.1016/J.BIOPHA.2021.111708 ↗
24. 10.3390/JCDD1206020710.3390/JCDD12060207 ↗
25. 10.3390/MOLECULES2714447810.3390/MOLECULES27144478 ↗
26. 10.1186/S43556-025-00352-W10.1186/S43556-025-00352-W ↗
27. 10.1016/J.ISCI.2024.10997910.1016/J.ISCI.2024.109979 ↗
28. 10.1016/J.SEMCANCER.2015.03.00510.1016/J.SEMCANCER.2015.03.005 ↗
29. 10.1186/S12935-024-03510-2/FIGURES/610.1186/S12935-024-03510-2/FIGURES/6 ↗
30. 10.15430/JCP.24.02710.15430/JCP.24.027 ↗
31. 10.1002/PRO.447910.1002/PRO.4479 ↗
32. 10.2174/187152652366623081615161410.2174/1871526523666230816151614 ↗
33. 10.1021/ACS.JCIM.0C0054510.1021/ACS.JCIM.0C00545 ↗
34. 10.2196/3718810.2196/37188 ↗
35. 10.1038/S42003-023-05243-W10.1038/S42003-023-05243-W ↗
36. 10.1111/BPH.7021510.1111/BPH.70215 ↗
37. 10.1016/J.XPRO.2025.10414410.1016/J.XPRO.2025.104144 ↗
38. 10.3390/IJMS26136506/S110.3390/IJMS26136506/S1 ↗
39. 10.1016/J.BBRC.2025.15197010.1016/J.BBRC.2025.151970 ↗
40. 10.1126/SCITRANSLMED.ABC8922/SUPPL_FILE/SCITRANSLMED.ABC8922_SM.PDF10.1126/SCITRANSLMED.ABC8922/SUPPL_FILE/SCITRANSLMED.ABC8922_SM.PDF ↗
41. 10.1016/j.celrep.2020.10866310.1016/j.celrep.2020.108663 ↗
42. 10.12998/WJCC.V11.I4.73810.12998/WJCC.V11.I4.738 ↗
43. 10.1002/PBC.30099;JOURNAL:JOURNAL:1096911X;REQUESTEDJOURNAL:.JOURNAL:15455017;WGROUP:STRING:PUBLICATION10.1002/PBC.30099;JOURNAL:JOURNAL:1096911X;REQUESTEDJOURNAL:.JOURNAL:15455017;WGROUP:STRING:PUBLICATION ↗
44. 10.2147/AABC.S6374910.2147/AABC.S63749 ↗
45. 10.1158/2159-8290.CD-19-0813/333456/AM/IMPAIRED-DEATH-RECEPTOR-SIGNALING-IN-LEUKEMIA10.1158/2159-8290.CD-19-0813/333456/AM/IMPAIRED-DEATH-RECEPTOR-SIGNALING-IN-LEUKEMIA ↗
46. 10.15171/APB.2017.04110.15171/APB.2017.041 ↗
47. 10.1016/B978-0-12-821618-7.00157-710.1016/B978-0-12-821618-7.00157-7 ↗
48. Gene Expression Is Analyzed by Tracking RNA. Learn Science at Scitable. (n.d.) [accessed 2025 19 May]. Available from: https://www.nature.com/scitable/topicpage/gene-expression-is-analyzed-by-tracking-rna-6525038/
49. 10.1080/21691401.2026.265558110.1080/21691401.2026.2655581 ↗
50. 10.1038/s41388-022-02487-410.1038/s41388-022-02487-4 ↗
51. 10.1038/S41419-021-04221-610.1038/S41419-021-04221-6 ↗
52. 10.1016/J.BBRC.2026.15408310.1016/J.BBRC.2026.154083 ↗
53. 10.1186/S12943-026-02620-X10.1186/S12943-026-02620-X ↗
54. 10.3389/FPHAR.2026.1764550/FULL10.3389/FPHAR.2026.1764550/FULL ↗
55. 10.3390/IJMS2707292410.3390/IJMS27072924 ↗
56. 10.1126/SCITRANSLMED.ABC892210.1126/SCITRANSLMED.ABC8922 ↗
57. 10.1016/j.matbio.2021.05.00610.1016/j.matbio.2021.05.006 ↗
58. 10.2353/AJPATH.2006.05095910.2353/AJPATH.2006.050959 ↗
59. 10.1158/0008-5472.CAN-20-219910.1158/0008-5472.CAN-20-2199 ↗
60. 10.1194/jlr.TR11900043910.1194/jlr.TR119000439 ↗
61. 10.1016/J.NANO.2020.10230710.1016/J.NANO.2020.102307 ↗
62. 10.1016/J.CELREP.2020.10866310.1016/J.CELREP.2020.108663 ↗
63. 10.1182/blood-2019-12786410.1182/blood-2019-127864 ↗
64. 10.1016/J.JBC.2024.10760110.1016/J.JBC.2024.107601 ↗
65. 10.1016/j.imu.2021.10066310.1016/j.imu.2021.100663 ↗
66. 10.1038/s41598-025-89097-810.1038/s41598-025-89097-8 ↗
67. 10.3389/FIMMU.2022.101512810.3389/FIMMU.2022.1015128 ↗
68. 10.1016/j.antiviral.2015.10.01410.1016/j.antiviral.2015.10.014 ↗
69. 10.1016/B978-0-323-89905-5.00003-310.1016/B978-0-323-89905-5.00003-3 ↗
70. 10.1186/S12967-024-05059-0/TABLES/110.1186/S12967-024-05059-0/TABLES/1 ↗